{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=18",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T05:08:24.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01569776",
      "title": "Elemental Formula Hypoallergenicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Food Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Amino Acid formula",
          "type": "OTHER"
        },
        {
          "name": "Commercially available Amino Acid Formula",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Société des Produits Nestlé (SPN)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Months to 12 Years"
      },
      "enrollment_count": 37,
      "start_date": "2012-04",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 9,
      "location_summary": "Huntington Beach, California • San Diego, California • Albany, Georgia + 6 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01569776"
    },
    {
      "nct_id": "NCT01209117",
      "title": "A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Human Immunodeficiency Virus and Herpesviridae",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2248761 WBM Capsule",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet Formulation 3",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761 WBM Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209117"
    },
    {
      "nct_id": "NCT00042289",
      "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "atazanavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "elvitegravir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "tenofovir alafenamide fumarate (TAF)",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat or ritonavir",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        },
        {
          "name": "darunavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir/tenofovir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        },
        {
          "name": "ethambutol",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        },
        {
          "name": "pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "kanamycin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "capreomycin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "levoflaxacin",
          "type": "DRUG"
        },
        {
          "name": "ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "ethionamide/prothionamide",
          "type": "DRUG"
        },
        {
          "name": "terizidone/cycloserine",
          "type": "DRUG"
        },
        {
          "name": "para-aminosalicylic acid (PAS)",
          "type": "DRUG"
        },
        {
          "name": "high dose INH",
          "type": "DRUG"
        },
        {
          "name": "bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "clofazamine",
          "type": "DRUG"
        },
        {
          "name": "delamanid",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "pretomanid",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel implant",
          "type": "DRUG"
        },
        {
          "name": "nevirapine",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "abacavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "didanosine delayed release (Videx® EC)",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "tipranavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #4",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        },
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "tenofovir/atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1578,
      "start_date": "2003-06-09",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042289"
    },
    {
      "nct_id": "NCT06208150",
      "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 838,
      "start_date": "2024-01-22",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 49,
      "location_summary": "Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06208150"
    },
    {
      "nct_id": "NCT01198418",
      "title": "A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sexually Transmitted Infections",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Experimental",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 181,
      "start_date": "2010-07-09",
      "completion_date": "2017-11-09",
      "has_results": false,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01198418"
    },
    {
      "nct_id": "NCT00339690",
      "title": "Dust Mite Allergen Reduction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergy"
      ],
      "interventions": [
        {
          "name": "MITE-T-FASTtest kit",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "National Institute of Environmental Health Sciences (NIEHS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "5 Years to 15 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-06-06",
      "completion_date": "2009-02-11",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00339690"
    },
    {
      "nct_id": "NCT01324310",
      "title": "Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Malignant Lymphoma"
      ],
      "interventions": [
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-04-01",
      "completion_date": "2012-01-01",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 2,
      "location_summary": "Sarasota, Florida • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01324310"
    },
    {
      "nct_id": "NCT03678259",
      "title": "124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Systemic Amyloidosis"
      ],
      "interventions": [
        {
          "name": "124I-p5+14 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-10-01",
      "completion_date": "2021-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03678259"
    },
    {
      "nct_id": "NCT01552603",
      "title": "Artificial Pancreas Control System in an Inpatient Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type I Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Artificial Pancreas Control Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Legacy Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-03",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552603"
    },
    {
      "nct_id": "NCT06469385",
      "title": "Topical ENS-002 for Atopic Dermatitis in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic Dermatitis Eczema"
      ],
      "interventions": [
        {
          "name": "ENS-002",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Concerto Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-09-18",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-18T05:08:24.956Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Beverly, Massachusetts • Austin, Texas",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Beverly",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06469385"
    }
  ]
}